Trial Profile

A randomized, observer-blinded, active-controlled, Phase IIIb study to compare IV / Oral delafloxacin fixed-dose monotherapy with best available treatments in a microbiologically enriched population with surgical site infections

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 19 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Delafloxacin (Primary) ; Delafloxacin (Primary) ; Linezolid; Linezolid; Piperacillin/tazobactam; Tigecycline; Vancomycin
Indications Bacterial infections; Skin and soft tissue infections; Surgical wound infections
Focus Registrational; Therapeutic Use
Acronyms DRESS
Sponsors Menarini Ricerche

05 Nov 2020 Status changed from recruiting to discontinued.
04 Nov 2020 This trial has been discontinued in Estonia and Bulgaria (Global End Date: 28 Oct 2020), according to European Clinical Trials Database record.
29 Oct 2020 This trial has been discontinued in Poland, according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com